FDA Clearance Tracker · P080015
CERVISTA HPV 16/18
Last checked: Nov 20, 2026Latest source record: Mar 12, 2009 (this decision)Source: openFDAMethods & limitations
Decided
Mar 12, 2009
Approval withdrawn
Time to decision
318 days
Received Apr 28, 2008. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P080015
- Device name
- CERVISTA HPV 16/18
- Applicant
- Hologic, Inc.
- Applicant location
- Malborough, MA
- Received
- Apr 28, 2008
- Decided
- Mar 12, 2009
- Decision
- Approval withdrawn
- Supplements
- 16 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THECERVISTA HPV 16/18.CERVISTA HPV 16/18 INDICATIONS FOR USE:THE CERVISTA HPV 16/18 TEST IS AN IN VITRO DIAGNOSTIC TEST FOR THE QUALITATIVE DETECTION OF DNA FROM HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 AND TYPE 18 IN CERVICAL SPECIMENS.THE CERVISTA HPV 16/18 TEST USES THE INVADER CHEMISTRY, A SIGNAL AMPLIFICATION METHOD FORDETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES. THIS METHOD USES TWO TYPES OF ISOTHERMAL REACTIONS:A PRIMARY REACTION THAT OCCURS ON THE TARGETED DNA SEQUENCE AND A SECONDARY REACTION THAT PRODUCES A FLUORESCENT SIGNAL.CERVISTA HPV 16/18 TEST IS INDICATED:1) IN WOMEN 30 YEARS AND OLDER THE CERVISTA HPV 16/1S TEST CAN BE USED ADJUNCTIVELYWITH THE CERVISTA HPV HR TEST IN COMBINATION WITH CERVICAL CYTOLOGY TO SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV TYPES 16 AND 18. THIS INFORMATION,TOGETHER WITH THE PHYSICIAN'S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT. 2) TO BE USED ADJUNCTIVELY WITH THE CERVISTA HPV HR TEST IN PATIENTS WITH ATYPICALSQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE (ASC-US) CERVICAL CYTOLOGY RESULTS, TOASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV TYPES 16 AND 18. THIS INFORMATION,TOGETHER WITH THE PHYSICIAN'S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT. THE RESULTS OF THIS TEST ARE NOT INTENDED TO PREVENT WOMEN FROM PROCEEDING TO COLPOSCOPY.CERVICAL SPECIMENS THAT MAY BE TESTED WITH THE CERVISTA HPV 16/18 TEST INCLUDE THE FOLLOWINGPRESERVATION SYSTEM AND COLLECTION DEVICES:THINPREP PAP TEST PRESERVCYT SOLUTION; AND¿ BROOM-TYPE DEVICE (E.G. ROVERS CERVEX BRUSH, WALLACH PAPETTE), OR ENDOCERVICALBRUSH/SPATULA.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MAQ. The earliest in FDA's data is P880009, decided Dec 23, 1988.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Hologic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- I-View®510(k)
K254090 · Decided Sep 2, 2026 · 257 days after receipt
Device type: Full Field Digital, System, X-Ray, Mammographic (MUE) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.